Resonant Medical develops, manufactures and commercializes 3D ultrasound image-guided adaptive radiotherapy products. Our goal is to help cancer centers make significant improvements in radiation therapy planning, verification and delivery – to advance patient care. We design high-performance products based on next-generation technologies that exceed the technical and clinical requirements of our customers while respecting the realities of operating cancer centers.
Geared for innovation
A privately-held company founded in 2000 by industry experts, Resonant is driven by 45 innovative employees with world-class expertise and experience. Our R&D group benefits from a unique mix of leading-edge clinical and computational expertise in radiotherapy, medical physics, ultrasound physics, sonography, image analysis and applied mathematics, while our Engineering team possesses over 100 years of combined experience in mission-critical visual software and hardware system development.
Active in clinical research
Our commitment to excellence is reflected in our numerous clinical research activities. Multiple aspects of our innovative technologies are being validated in real clinical settings, and we enjoy frequent collaborations with clinics and academic institutions across the continent.
Committed to quality and regulatory best practices
Our commitment to manufacturing high-quality, safe and reliable medical equipment is demonstrated by our stringent quality system and ISO 13485 certification. ISO 13485 is a Quality Management System for Medical Devices and demands strict adherence to the design, manufacturing and service processes that govern the development of medical devices.
In addition, Resonant respects the principles and practices related to the protection of patient privacy. We strive to develop products that facilitate our customers’ compliance to state and federal statutes, and work with them to ensure that Protected Health Information (PHI) is secure through education, as well as company policies and procedures.
Dedicated to a mutually rewarding customer-vendor experience
Most importantly, our entire organization is focused on providing a unique level of customer care and support. Resonant was founded by clinicians with a deep understanding of, and respect for the needs, expectations and requirements of cancer centers. Our business development and customer support teams have cumulated years of clinical experience in cancer centers, as well as industry experience with established vendors, and all are highly motivated to support customers.
Tony Falco, PhD
Luc Sirois, MBA (Harvard)
Martin Lachaine, PhD
Allen R. Belinko
Mark Broeders, MBA
Geralyn Ochab, ARDMS
Rui Castro Lopes, MBA
Frederick S. Nagy, MSc (Biochemistry)
Pierre Lecavalier, MScA
Bob Donovan, Eng
Mark Carol, MD
Floyd Dunn, PhD
Aaron Fenster, PhD
Shirley Lehnert, PhD
Gerard Morton, MB, MRCPI, FRCPC
Resonant Medical enjoys the support of the following committed investors:
In 2005, Resonant secured the largest medical device venture capital financing in Canada, worth $24 in series B financing.